Editorial: Endocrine disruptors in gut endocrinology
Velmurugan Ganesan,Marica Colella,Luigi Santacroce
DOI: https://doi.org/10.3389/fendo.2024.1536495
IF: 6.055
2024-12-14
Frontiers in Endocrinology
Abstract:Interactions between the endocrine system, gut microbiota, and endocrine disruptors are multifaceted study areas with significant implications for human health. The research topic "Endocrine Disruptors in Gut Endocrinology" aims to offer an up-to-date overview of these components and their interconnections. Disruptions in the endocrine system compromise hormone production, potentially leading to various health issues, including obesity, diabetes, gastrointestinal and reproductive disorders, and endocrinerelated cancers. hile Conversely, gut microbiota plays several essential roles, including immune and hormonal regulation, influencing systemic inflammation and susceptibility to infections, and helping the digestion of complex carbohydrates, fats, and proteins, producing short-chain fatty acids (SCFAs) and other metabolites that contribute to gut health and systemic metabolism. Due to the close connection of the gut and oral microbiotas, any intestinal dysbiosis may alter the physiologic state of the oral one, influencing local and systemic conditions (Santacroce, 2010).For this reason, gut microbiota may be a useful tool for both diagnosis and therapy in certain clinical conditions (Di Domenico, 2022).Keywords: Endocrine gut, endocrine disruptors, gut microbiota, gut-brain axis, hormonal imbalance.Endocrine disruptors are synthetic or natural chemicals that can interfere with the body's endocrine (hormonal) system. They can mimic or inhibit hormones and influence various pathways, potentially leading to adverse health effects (Charitos, 2022).Common sources of endocrine disruptors include molecules usually present in personal care products as well as in vegetables (i.e., phthalates, parabens, and organophosphates), and plastics (e.g., bisphenol A -BPA) (Endocrine Society, 2024).Exposure to endocrine disruptors can lead to changes in the composition and diversity of gut microbiota, contributing to dysbiosis. Dysbiosis is associated with several disorders, including obesity, metabolic syndrome, acute and chronic renal diseases, and inflammatory bowel diseases.Gut microbiota can metabolize endocrine disruptors, potentially detoxifying them or, conversely, converting them into more harmful metabolites. The interplay between gut bacteria and these chemicals influences systemic exposure levels and toxicity.Dysbiosis of gut microbiota from endocrine disruptor exposure may contribute to increased gut permeability (or "leaky gut"), which can lead to systemic inflammation and further endocrine system imbalances.Gut microbiota metabolism affects hormone levels, such as the deconjugation of estrogens and their subsequent reabsorption or excretion. This can influence estrogen levels and activity in the body, impacting reproductive health and risks of hormone-mediated cancers.Furthermore, recent research shows that intestinal microbial metabolites are fundamental for local neuroendocrine regulation and drug metabolism. In detail, such metabolites can allow a higher efficacy of anti-tumor drugs and diabetes control. (Liu, 2022;Zhu, 2023;Niu. 2024;Tuohongerbieke, 2024;Toft, 2024) The gut microbiota can influence the endocrine system through the gut-brain axis, affecting stress responses and behavior. This interaction may affect mental health, especially regarding hormonal influences (Montagnani, 2023).The research topic "Endocrine Disruptors in Gut Endocrinology" hosts four published manuscripts reporting original contributions in the field.Liang M. and coll. offer a notable contribution to personalized medicine with the paper "Diagnostic model for predicting hyperuricemia based on alterations of the gut microbiome in individuals with different serum uric acid levels". They defined the differences in the gut microbiome among participants with different uric acid levels to develop a model to predict hyperuricemia based on 12 new microbial biomarkers (Liang, 2022).Liu L. and coll. contributed a real-world vision of commercially available glucagon-like peptide-1 receptor agonists (GLP-1 RAs) efficacy in glycemic control. Their paper "Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database" provides valuable evidence for selecting appropriate GLP-1 RAs to avoid undesired gastrointestinal side effects (Liu, 2022).Zhu Z. and coll. published the paper "Examination of the mechanism of Piezo ion channel in 5-HT synthesis in the enterochromaffin cell and its association with gut motility". It is an interesting contribution to understand better how human-derived enterochromaffin cells that functionally express Piezo ion channels are associated with cellular mechanosensation via serotonin in peristalsis regulation (Zhu, 2023).Toft PB. and coll. also contributed in understanding intestinal peristalsis. Their paper "Microbial metabolite p-cresol inhibits gut ho -Abstract Truncated-
endocrinology & metabolism